Alterity Therapeutics Files 6-K, Incorporates Filings
Ticker: PRNAF · Form: 6-K · Filed: Dec 31, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Dec 31, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, registration-statement, foreign-private-issuer
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K, incorporating old S-8/F-3 filings. Nothing new, just housekeeping.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on December 31, 2024, to report information as a foreign private issuer. This filing incorporates by reference previous registration statements on Form S-8 and Form F-3. The report includes Exhibit 99.1, a notification regarding unquoted securities.
Why It Matters
This filing updates the company's reporting status and incorporates existing registration statements, which may be relevant for investors tracking the company's ongoing securities offerings and compliance.
Risk Assessment
Risk Level: low — The filing is primarily a procedural update and incorporation of existing documents, not announcing new material events or financial results.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- Form S-8 (document) — Incorporated by reference
- Form F-3 (document) — Incorporated by reference
- Exhibit 99.1 (document) — Included in filing
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is filed by Alterity Therapeutics Ltd. as a report of a foreign private issuer for the month of December 2024, and it incorporates by reference several existing registration statements.
Which registration statements are being incorporated by reference?
The filing incorporates by reference Alterity Therapeutics Ltd.'s Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is included as an exhibit in this filing?
Exhibit 99.1, a notification regarding unquoted securities, is submitted with this Form 6-K.
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Alterity Therapeutics indicates it files annual reports under Form 20-F.
Filing Stats: 188 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-12-31 08:00:01
Filing Documents
- ea0226380-6k_alterity.htm (6-K) — 14KB
- ea022638001ex99-1_alterity.htm (EX-99.1) — 42KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- 0001213900-24-113673.txt ( ) — 59KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Notification regarding unquoted securities 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: December 31, 2024 2